Proposed Directors of Tirupati Graphite explain why they have requisitioned an GM. Watch the video here.
Cmc it may be prudent to sell your holding, before i get shot down here's my reasons: 1. By the sounds of it you got in later than most on this board in fact some have probably been here since the early days and have more than likely derisked over that period in that they have been topslicing profit and are probably running risk free. 2. This is the riskiest period as the results due in a week or two will decide the next step for the company and the sp, if they are good then it proves the platform used in the formulation of the oxpzero ibu is transferable,to the other nsaids and opens up a massive market if not then they will have to go back and work on the formulation which with the recent placing they have the funding to do. 3. As for the woodford effect it is doubtful he has a crystal ball and would have been privy to any more information on the naprosyn is doubtful (two weeks to run a full trial with endoscopic examinations and pk data analysis) before the annoucement of the proposed placing.come on ! 4. If the results are good you will have plenty of time to get back in, yeah the sp will rise but oxp still have a lot of work to do to get to that 50p level and beyond i think people have glossed over the fact that the original study for oxpzero ibuprofen last year failed to show bioequivalence and this coming trial is the 2nd attempt. I wouldn't underestimate the riskyness of this venture as i am sure woodford won't have if it was easy as some seem to think one of the big pharma would have done it a long time ago ---0.35 of his equity income fund although probably slightly more if you take into account the placing, got to be worth a punt.
Depends on whether you are an optimist or pessimist: The last rns could be taken either way, on one hand you could read that oxp more than likely know the naprox results and they aren't good hence the reason they have sped up the trial on ibu, hoping that the results from this trial will limit the damage from the naprox as it would bring into question the technology. On the other hand you could read that the results are good and oxp want to deliver a double whammy in quick sucession of positive trial data, either way its a judgement call
A vast propotion of shares are held by investment firms so there aren't that many on the open market so any resonably large buys/sells have an increased effect on the market due to the availability of stock.
It's either someone getting rid of a holding to get into something else or, worst case someone knows something.
To answer your question smokey2 mg/al hydroxides are fundamental in what oxp are trying to achieve with their oxpzero formulations to say they are not using them is wrong. There is always a flipside the sp can also move as quickly down as it can up and whose to say that Woodford was party to all the info at the end of the day woodfords holding in overall relation to the rest of his portfolio is small. All I am saying is that sometimes when things are too good to be true ..... I hope that these crucial next results are good and the sp rises in accordance and I will be buying back in but for the time being I have reduced my holding awaiting further news GLA
Sorry ignore the pozen bit from reading the guys posts he seems to know a great deal about pharmaceutical compounds and excipients it was his post about the previous rns results which madebe go back and re read: The announcement on the OXP005 PK results this morning sound a cautionary note. The C max for OXP005 was numerically lower (which is no surprise to me) and they obviously could not show that the 90% interval fell within the required 80 – 125% limits. Furthermore 82% is worryingly close to the 80% lower limit (which is also no surprise to me). They state that the dose given was low in the test material. That sounds like they are looking for retrospective excuses. It may well have been a lower dose, or it may have been smack on the target dose (i.e 250mg/tablet) but instead the analytical method was only 98% accurate, who knows? Whatever, it raises the question, if there was any doubt about the quality of the test material, why didnt they manufacture another batch which was closer to the target specification? What would be the consequences of a lower Cmax when they conduct the next pivotal PK study? The drug is being absorbed more slowly, so it will probably act more slowly, this means that they may be required to conduct extensive additional clinical trials to demonstrate that OXP005 is equivalent to standard Naprtoxen with respect to pain relief (so called non-inferiority studies). These studies may not give the outcome that is desired. Needless to say, OXP are likely to encounter similar problems with ibuprofen (the problem is likely to be exacerbated for ibuprofen, as ibuprofen is more rapidly absorbed than naproxen, so any retardation of absorption will be more pronounced). A market cap of £110m looks expensive to me given all these uncertainties. Anyway long story short i have sold a fair amount of my holding, i am not encoraging others to do the same i have made a fair amount of profit just i am a pi not an investment company so i cant afford to lose, i wish everyone luck and hope the results are good but dyor and don't necessarily follow the herd
Taken from advfn re recent placing :It's certainly prudent of management to raise cash at this small discount before the results are out for the on-going endoscopy study. If that one fails (or has an ambivalent outcome) then they really are in trouble. I suspect looking at Aspirin will be another wild goose chase, but for different reasons than ibuprofen and Naproxen. First of all there could be a stability issue. Aspirin breaks down readily to Salicylic acid and acetic acid in the presence of alkali (for example Magnesium/Aluminium Hydroxide), although they should be able to overcome this by using controlled humidity manufacturing and packaging conditions along with moisture resistant packaging (for example Aluminium foil lined sachets). Aspirin is unlikely to have the same sort of affinity for the Magnesium/Aluminium Hydroxide compared to either ibuprofen or naproxen, which from a bioavailability perspective is good and I think there is a reasonable chance it will be bioequivalent to the controls for both Cmax and AUC, however the flip side is that it is unlikely to be significantly different to the appropriate controls on GI side effects. The controls should include low dose buffered aspirin, not just low dose regular aspirin, for example these products: http://www.drugs.com/otc/106433/bufferin-low-dose-buffered-aspirin.html https://www.wonderdrug.com/products/bayer-women-low-dose-aspirin/ Finally as explained in detail in previous posts, Safestat is just a pipe dream, they don't seem to have any data to support the hypothesis and as for a talk of combining Safestat with OXPzero Aspirin, pigs might fly.